XSWX:BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XSWX:BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bristol-Myers Squibb Co XSWX:BMY
Bristol-Myers Squibb Co XSWX:BMY +1.42% 78 Beneish M-Score is -2.73 as of Jul. 24, 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 78/100 and a GF Value™ of CHF45.07. The stock has 7 warning signs investors should review. Among 910 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 70.22% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Bristol-Myers Squibb Co's Beneish M-Score or its related term are showing as below:
During the past 13 years, the highest Beneish M-Score of Bristol-Myers Squibb Co was -1.66. The lowest was -3.34. And the median was -2.81.
The historical data trend for Bristol-Myers Squibb Co's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Bristol-Myers Squibb Co Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| Beneish M-Score | Get a 7-Day Free Trial |
|
|
-2.81 | -2.70 | -2.79 | -3.15 | -2.60 | |||||||||||||
| Bristol-Myers Squibb Co Quarterly Data | ||||||||||||||||||||
| Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | |
| Beneish M-Score | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
-2.87 | -2.90 | -2.85 | -2.60 | -2.73 | ||
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Bristol-Myers Squibb Co for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 0.7985 | + | 0.528 * 0.9991 | + | 0.404 * 1.0059 | + | 0.892 * 0.9244 | + | 0.115 * 1.7151 | |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
| - | 0.172 * 0.94 | + | 4.679 * -0.0454 | - | 0.327 * 0.9419 | |||||||
| = | -2.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar26) TTM: | Last Year (Mar25) TTM: |
| Total Receivables was CHF9,513 Mil. Revenue was 9045.29 + 9963.641 + 9729.934 + 9977.151 = CHF38,716 Mil. Gross Profit was 6351.936 + 6698.741 + 6995.331 + 7235.04 = CHF27,281 Mil. Total Current Assets was CHF21,421 Mil. Total Assets was CHF68,083 Mil. Property, Plant and Equipment(Net PPE) was CHF7,233 Mil. Depreciation, Depletion and Amortization(DDA) was CHF2,873 Mil. Selling, General, & Admin. Expense(SGA) was CHF5,828 Mil. Total Current Liabilities was CHF15,083 Mil. Long-Term Debt & Capital Lease Obligation was CHF34,580 Mil. Net Income was 2107.602 + 866.23 + 1752.216 + 1065.292 = CHF5,791 Mil. Non Operating Income was 223.593 + -724.382 + -35.028 + -1233.624 = CHF-1,769 Mil. Cash Flow from Operations was 869.179 + 1573.081 + 5024.187 + 3185.304 = CHF10,652 Mil. |
Total Receivables was CHF12,888 Mil. Revenue was 9897.204 + 11004.127 + 10074.902 + 10905.254 = CHF41,881 Mil. Gross Profit was 7217.245 + 6713.748 + 7569.732 + 7985.209 = CHF29,486 Mil. Total Current Assets was CHF27,200 Mil. Total Assets was CHF81,668 Mil. Property, Plant and Equipment(Net PPE) was CHF7,447 Mil. Depreciation, Depletion and Amortization(DDA) was CHF7,087 Mil. Selling, General, & Admin. Expense(SGA) was CHF6,707 Mil. Total Current Liabilities was CHF21,268 Mil. Long-Term Debt & Capital Lease Obligation was CHF41,982 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (9512.946 / 38716.016) | / | (12888.19 / 41881.487) | |
| = | 0.245711 | / | 0.30773 | |
| = | 0.7985 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
| = | (29485.934 / 41881.487) | / | (27281.048 / 38716.016) | |
| = | 0.704033 | / | 0.704645 | |
| = | 0.9991 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (21420.858 + 7232.925) / 68082.555) | / | (1 - (27199.859 + 7446.981) / 81668.497) | |
| = | 0.579132 | / | 0.575762 | |
| = | 1.0059 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 | |
| = | 38716.016 | / | 41881.487 | |
| = | 0.9244 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (7086.658 / (7086.658 + 7446.981)) | / | (2873.229 / (2873.229 + 7232.925)) | |
| = | 0.487604 | / | 0.284305 | |
| = | 1.7151 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (5828.338 / 38716.016) | / | (6707.324 / 41881.487) | |
| = | 0.150541 | / | 0.16015 | |
| = | 0.94 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((34579.791 + 15083.093) / 68082.555) | / | ((41982.487 + 21268.252) / 81668.497) | |
| = | 0.729451 | / | 0.774481 | |
| = | 0.9419 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
| = | (5791.34 - -1769.441 | - | 10651.751) | / | 68082.555 | |
| = | -0.0454 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Bristol-Myers Squibb Co has a M-score of -2.83 suggests that the company is unlikely to be a manipulator.
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.
Key valuation signals for XSWX:BMY:
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.